Table 2.

Relative risk of colorectal cancer according to quintiles of CML-AGE, sRAGE-adjusted CML-AGE and sRAGE

Quintiles (Q)
CML-AGE	Q1	Q2	Q3	Q4	Q5	P value for trenda
Case/subcohort	81/97	136/97	101/97	104/97	61/97
RRb (95% CI)	1.0 (ref)	1.60 (1.05–2.42)	1.16 (0.76–1.78)	1.38 (0.89–2.13)	0.69 (0.43–1.08)	0.12
RRc (95% CI)	1.0 (ref)	1.74 (1.13–2.68)	1.22 (0.78–1.90)	1.34 (0.85–2.11)	0.71 (0.44–1.14)	0.13
RRd (95% CI)	1.0 (ref)	2.18 (1.34–3.56)	1.49 (0.91–2.42)	1.74 (1.05–2.89)	0.97 (0.55–1.70)	0.62
RRe (95% CI)	1.0 (ref)	1.84 (1.05–3.22)	1.45 (0.83–2.53)	1.83 (1.03–3.26)	1.20 (0.64–2.26)	0.51
Adjusted CML-AGEf
Case/subcohort	68/97	134/97	111/97	103/97	67/97
RRb (95% CI)	1.0 (ref)	1.93 (1.26–2.95)	1.62 (1.05–2.49)	1.46 (0.95–2.27)	1.01 (0.64–1.61)	0.70
RRc (95% CI)	1.0 (ref)	2.03 (1.31–3.16)	1.63 (1.03–2.56)	1.58 (1.00–2.49)	1.01 (0.63–1.63)	0.67
RRd (95% CI)	1.0 (ref)	2.32 (1.44–3.72)	1.89 (1.16–3.08)	1.77 (1.10–2.86)	1.19 (0.71–1.99)	0.91
RRe (95% CI)	1.0 (ref)	2.19 (1.26–3.82)	2.19 (1.26–3.80)	1.84 (1.05–3.21)	1.66 (0.92–3.00)	0.17
sRAGE
Case/subcohort	102/97	116/97	97/97	86/97	82/97
RRb (95% CI)	1.0 (ref)	1.00 (0.66–1.50)	0.83 (0.55–1.26)	0.76 (0.50–1.17)	0.68 (0.44–1.04)	0.03
RRc (95% CI)	1.0 (ref)	1.06 (0.69–1.63)	0.91 (0.59–1.41)	0.79 (0.51–1.23)	0.68 (0.44–1.06)	0.03
RRd (95% CI)	1.0 (ref)	1.02 (0.65–1.60)	0.87 (0.55–1.38)	0.76 (0.47–1.23)	0.65 (0.39–1.07)	0.03
RRe (95% CI)	1.0 (ref)	0.86 (0.52–1.40)	0.70 (0.41–1.18)	0.60 (0.35–1.01)	0.52 (0.30–0.89)	0.009

^aCalculated by assigning the median value of each quintile as a continuous variable and included in the model.

^bModel 1: Crude RR.

^cModel 2: RR was adjusted for age.

^dModel 3: RR was adjusted for age, years of smoking, BMI, and serum sRAGE (for CML-AGE) or serum CML-AGE (for sRAGE).

^eModel 4: RR was adjusted for serum glucose in addition to model 3.

^fThe serum CML-AGE was adjusted for sRAGE using the residual method.

AGEs, advanced glycation end-products; sRAGE, soluble receptor for advanced glycation end-products.